- Home
- ALKT vs IMVT Comparison
ALKT vs IMVT Comparison
Compare ALKT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- IMVT
- Stock Information
- Founded
- ALKT 2007
- IMVT 2018
- Country
- ALKT United States
- IMVT United States
- Employees
- ALKT N/A
- IMVT N/A
- Industry
- ALKT EDP Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALKT Technology
- IMVT Health Care
- Exchange
- ALKT Nasdaq
- IMVT Nasdaq
- Market Cap
- ALKT 3.1B
- IMVT 2.8B
- IPO Year
- ALKT 2021
- IMVT N/A
- Fundamental
- Price
- ALKT $27.95
- IMVT $15.80
- Analyst Decision
- ALKT Buy
- IMVT Buy
- Analyst Count
- ALKT 9
- IMVT 10
- Target Price
- ALKT $39.89
- IMVT $40.14
- AVG Volume (30 Days)
- ALKT 856.2K
- IMVT 1.3M
- Earning Date
- ALKT 07-30-2025
- IMVT 08-05-2025
- Dividend Yield
- ALKT N/A
- IMVT N/A
- EPS Growth
- ALKT N/A
- IMVT N/A
- EPS
- ALKT N/A
- IMVT N/A
- Revenue
- ALKT $355,557,000.00
- IMVT N/A
- Revenue This Year
- ALKT $36.09
- IMVT N/A
- Revenue Next Year
- ALKT $24.79
- IMVT N/A
- P/E Ratio
- ALKT N/A
- IMVT N/A
- Revenue Growth
- ALKT 26.55
- IMVT N/A
- 52 Week Low
- ALKT $21.70
- IMVT $12.72
- 52 Week High
- ALKT $42.29
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- ALKT 46.15
- IMVT 53.39
- Support Level
- ALKT $26.70
- IMVT $15.11
- Resistance Level
- ALKT $31.18
- IMVT $17.08
- Average True Range (ATR)
- ALKT 0.99
- IMVT 0.76
- MACD
- ALKT -0.28
- IMVT -0.00
- Stochastic Oscillator
- ALKT 29.32
- IMVT 47.56
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.